3 results
Approved WMOCompleted
To evaluate the efficacy of Lanreotide Autogel 120 mg when used as primary medical treatment in untreated de novo acromegalic patients with macroadenoma
Approved WMOCompleted
The purpose of this study is to look at the effect of changing from monthly (4 weekly) injections of your usual treatment (octreotide LAR) to less frequent treatment (once every 6 or 8 weeks) with lanreotide Autogel 120 mg injections. The study…
Approved WMOCompleted
In this feasibility study, we will validate the value of the preoperative [89Zr]trastuzumab PET/CT imaging to identify HER2 positive primary breast cancer and the possibility to predict pathological complete response.